Epigenomics AG reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was EUR 0.339227 million compared to EUR 0.899 million a year ago. Net loss was EUR 4.46 million compared to EUR 1,730.4 million a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.05 EUR | +0.48% | -29.05% | -44.44% |
Apr. 30 | Epigenomics AG Announces Jens Ravens Leaves as Executive Board Member | CI |
Mar. 14 | Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-44.44% | 987K | |
-39.38% | 8.28B | |
+9.28% | 3.62B | |
-1.48% | 2.24B | |
-22.85% | 1.94B | |
-18.07% | 1.72B | |
+10.53% | 962M | |
+17.17% | 734M | |
-9.17% | 690M | |
-33.88% | 477M |
- Stock Market
- Equities
- ECX Stock
- News Epigenomics AG
- Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023